Jeff Johnson
Stock Analyst at Baird
(4.61)
# 115
Out of 4,814 analysts
143
Total ratings
55.79%
Success rate
30.61%
Average return
Main Sectors:
Stocks Rated by Jeff Johnson
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| COO The Cooper Companies | Maintains: Outperform | $117 → $107 | $79.55 | +34.51% | 16 | Mar 7, 2025 | |
| TNDM Tandem Diabetes Care | Maintains: Neutral | $37 → $33 | $16.86 | +95.79% | 15 | Feb 27, 2025 | |
| ALC Alcon | Maintains: Outperform | $104 → $108 | $92.47 | +16.79% | 9 | Feb 27, 2025 | |
| BBNX Beta Bionics | Initiates: Neutral | $20 | $11.18 | +78.89% | 1 | Feb 20, 2025 | |
| DXCM DexCom | Upgrades: Outperform | $86 → $104 | $68.61 | +51.58% | 13 | Jan 16, 2025 | |
| PDCO Patterson Companies | Maintains: Neutral | $25 → $31 | $31.33 | -1.05% | 7 | Dec 12, 2024 | |
| NVST Envista Holdings | Maintains: Neutral | $17 → $22 | $15.19 | +44.83% | 7 | Oct 31, 2024 | |
| SYK Stryker | Maintains: Outperform | $378 → $405 | $346.60 | +16.85% | 11 | Oct 30, 2024 | |
| ALGN Align Technology | Maintains: Outperform | $325 → $276 | $171.41 | +61.02% | 18 | Oct 24, 2024 | |
| ZBH Zimmer Biomet Holdings | Maintains: Outperform | $155 → $145 | $97.88 | +48.14% | 13 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $92 → $82 | $64.28 | +27.57% | 9 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $180 → $238 | $246.95 | -3.62% | 12 | Dec 21, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $67 → $70 | $31.89 | +119.50% | 2 | Aug 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $53 → $61 | $14.92 | +308.85% | 4 | Jul 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $78 → $67 | $12.84 | +421.81% | 6 | Feb 18, 2022 |
The Cooper Companies
Mar 7, 2025
Maintains: Outperform
Price Target: $117 → $107
Current: $79.55
Upside: +34.51%
Tandem Diabetes Care
Feb 27, 2025
Maintains: Neutral
Price Target: $37 → $33
Current: $16.86
Upside: +95.79%
Alcon
Feb 27, 2025
Maintains: Outperform
Price Target: $104 → $108
Current: $92.47
Upside: +16.79%
Beta Bionics
Feb 20, 2025
Initiates: Neutral
Price Target: $20
Current: $11.18
Upside: +78.89%
DexCom
Jan 16, 2025
Upgrades: Outperform
Price Target: $86 → $104
Current: $68.61
Upside: +51.58%
Patterson Companies
Dec 12, 2024
Maintains: Neutral
Price Target: $25 → $31
Current: $31.33
Upside: -1.05%
Envista Holdings
Oct 31, 2024
Maintains: Neutral
Price Target: $17 → $22
Current: $15.19
Upside: +44.83%
Stryker
Oct 30, 2024
Maintains: Outperform
Price Target: $378 → $405
Current: $346.60
Upside: +16.85%
Align Technology
Oct 24, 2024
Maintains: Outperform
Price Target: $325 → $276
Current: $171.41
Upside: +61.02%
Zimmer Biomet Holdings
Aug 8, 2024
Maintains: Outperform
Price Target: $155 → $145
Current: $97.88
Upside: +48.14%
Aug 7, 2024
Maintains: Outperform
Price Target: $92 → $82
Current: $64.28
Upside: +27.57%
Dec 21, 2023
Upgrades: Outperform
Price Target: $180 → $238
Current: $246.95
Upside: -3.62%
Aug 4, 2023
Maintains: Outperform
Price Target: $67 → $70
Current: $31.89
Upside: +119.50%
Jul 28, 2023
Maintains: Outperform
Price Target: $53 → $61
Current: $14.92
Upside: +308.85%
Feb 18, 2022
Maintains: Outperform
Price Target: $78 → $67
Current: $12.84
Upside: +421.81%